Literature DB >> 22041330

Left ventricular geometry, global function, and dyssynchrony in infants and children with pompe cardiomyopathy undergoing enzyme replacement therapy.

Chun-An Chen1, Yin-Hsiu Chien, Wuh-Liang Hwu, Ni-Chung Lee, Jou-Kou Wang, Lei-Ru Chen, Chun-Wei Lu, Ming-Tai Lin, Shuenn-Nan Chiu, Hsin-Hui Chiu, Mei-Hwan Wu.   

Abstract

BACKGROUND: Enzyme replacement therapy (ERT) for infantile-onset Pompe disease effectively reduces the left ventricular (LV) mass. This study sought to explore detailed process of LV reverse remodeling after ERT with the use of tissue Doppler and stain rate imaging. METHODS AND
RESULTS: Nine infants and children with Pompe cardiomyopathy undergoing ERT for ≥1 year, as well as 36 healthy control subjects, were studied. Global systolic and diastolic function was evaluated by peak systolic and early-diastolic velocity at mitral annulus. Temporal systolic and diastolic dyssynchrony was evaluated by the coefficient of variation of the time from the QRS complex to peak systolic and early-diastolic strain rate among 12 LV segments. All pre-ERT patients had impaired global systolic and diastolic function as well as increased regional dyssynchrony (P < .001 for each of all). During the regression of LV hypertrophy, all of these functional indices improved (P for trend <.001), with temporal diastolic dyssynchrony being a significant factor linking to LV mass index in multivariate analysis (P < .001).
CONCLUSIONS: ERT improved global LV function and dyssynchrony in Pompe patients. The relationship between LV mass and temporal diastolic dyssynchrony during reverse remodeling suggested a pathophysiologic role of dyssynchrony in Pompe cardiomyopathy. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22041330     DOI: 10.1016/j.cardfail.2011.07.011

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  6 in total

1.  Structural and functional cardiac analyses using modern and sensitive myocardial techniques in adult Pompe disease.

Authors:  Daniel A Morris; Daniela Blaschke; Alice Krebs; Sima Canaan-Kühl; Ursula Plöckinger; Gesine Knobloch; Thula C Walter; York Kühnle; Leif-Hendrik Boldt; Elisabeth Kraigher-Krainer; Burkert Pieske; Wilhelm Haverkamp
Journal:  Int J Cardiovasc Imaging       Date:  2015-03-06       Impact factor: 2.357

2.  Epidemiology of Cardiomyopathy in Taiwanese Population Aged Younger Than 65 Years.

Authors:  Po-Yuan Wang; En-Ting Wu; Frank Leigh Lu; Jyh-Ming Jimmy Juang; Feng-Yu Kao; San-Kuei Huang; Mei-Hwan Wu
Journal:  Acta Cardiol Sin       Date:  2022-09       Impact factor: 1.800

Review 3.  Beyond Sarcomeric Hypertrophic Cardiomyopathy: How to Diagnose and Manage Phenocopies.

Authors:  Maurizio Pieroni; Michele Ciabatti; Elisa Saletti; Valentina Tavanti; Pasquale Santangeli; Lucia Martinese; Francesco Liistro; Iacopo Olivotto; Leonardo Bolognese
Journal:  Curr Cardiol Rep       Date:  2022-09-02       Impact factor: 3.955

4.  Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Kunil K Raval; Ran Tao; Brent E White; Willem J De Lange; Chad H Koonce; Junying Yu; Priya S Kishnani; James A Thomson; Deane F Mosher; John C Ralphe; Timothy J Kamp
Journal:  J Biol Chem       Date:  2014-12-08       Impact factor: 5.157

5.  Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.

Authors:  Manuela Corti; Cristina Liberati; Barbara K Smith; Lee Ann Lawson; Ibrahim S Tuna; Thomas J Conlon; Kirsten E Coleman; Saleem Islam; Roland W Herzog; David D Fuller; Shelley W Collins; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2017-12       Impact factor: 5.032

6.  Advancements in AAV-mediated Gene Therapy for Pompe Disease.

Authors:  S M Salabarria; J Nair; N Clement; B K Smith; N Raben; D D Fuller; B J Byrne; M Corti
Journal:  J Neuromuscul Dis       Date:  2020
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.